Taken together, our data reveal that the oncosuppressor P53 counteracts NKX3-2 expression in ovarian cancer cells and supports the prognostic value of NKX3-2 for the stratification of cancer patients in a view of precision medicine. Here, TP53 is linked to ovarian cancer.